The invention belongs to the technical field of
biology, and particularly relates to an application of GTPBP4
protein as an immunosuppressant and construction of a knockdown or overexpression GTPBP4
cell line. Firstly, it is accidentally found that GTPBP4 inhibits activation of an IFN-beta
promoter induced by SeV (
Sendai virus) and
mRNA expression of IFN beta and downstream genes of IFN beta, andinhibits IFN-beta
protein expression induced by SeV; and targeted IRF3 (
interferon reaction factor 3) inhibits innate
immunity; secondly, overexpression of the GTPBP4
protein in the
cell line significantly promotes expression of the
Senecavirus VP1 protein, improves the
Senecavirus titer, and can be used for construction of
Senecavirus and
vaccine production cell lines; and finally, the GTPBP4 protein is knocked down in the cell line, expression of the Senecavirus VP1 protein is obviously inhibited, the
titer of the Senecavirus is reduced, and the cell line can be used for breeding animals resisting Senecavirus infection. The GTPBP4 protein inhibitor can be used for preparing medicines, pharmaceutical compositions or vaccine compositions for preventing or treating
virus infection of the small ribonucleic acid viruses.